🇺🇸 FDA

Company profile · Sponsor

PUMA

PUMA BIOTECHNOLOGY, INC.

PBYI · NYSE biotech LOS ANGELES, CA, USA
Pipeline
24
Drugs
1
Patents
1

Quick answer

PUMA (PBYI) is a biotech company. headquartered in LOS ANGELES, CA, USA. listed on NYSE. NovaPharmaNews links 24 pipeline programs, 1 drug, and 1 patent to this profile..

Company facts

Ticker PBYI
Exchange NYSE
Company type biotech
Headquarters LOS ANGELES, CA, USA
SEC CIK 0001401667

Pipeline (24)

Search pipeline →

  1. Neratinib

    PUMA

    Breast Cancer

    phase 3 small molecule active

    8 trials

  2. neratinib

    PUMA

    HER2+ Metastatic Breast Cancer (MBC)

    phase 3 small molecule completed

    1 trial

  3. Alisertib

    PUMA

    Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  4. Alisertib

    PUMA

    Small Cell Lung Cancer ( SCLC )

    phase 2 small molecule active

    1 trial

  5. Alisertib

    PUMA

    Hormone Receptor Positive HER-2 Negative Breast Cancer

    phase 2 small molecule active

    1 trial

  6. Capecitabine

    PUMA

    Breast Cancer

    phase 2 small molecule active

    1 trial

  7. Fulvestrant STADA 250 mg injekcinis tirpalas užpildytame švirkšte, Alisertib Enteric-Coated Tablets, Exemestane SanoSwiss 25 mg plėvele dengtos tabletės, Anastrozole Accord 1 mg plėvele dengtos tabletės, Letrozole SanoSwiss 2,5 mg plėvele dengtos tabletės, Tamoxifen EBEWE 20 mg tabletės

    PUMA

    Hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) recurrent or metastatic breast cancer (MBC)

    phase 2 small molecule active

    1 trial

  8. HKI-272

    PUMA

    Breast Cancer

    phase 2 small molecule completed

    1 trial

  9. HKI-272

    PUMA

    Carcinoma, Non-Small-Cell Lung

    phase 2 small molecule completed

    1 trial

  10. HKI-272

    PUMA

    Advanced Breast Cancer

    phase 2 small molecule completed

    2 trials

  11. NERATINIB

    PUMA

    Stage IV (Metastatic) Breast Cancer

    phase 2 small molecule terminated

    1 trial

  12. Neratinib

    PUMA

    Metastatic Prostate Adenocarcinoma

    phase 2 small molecule terminated

    1 trial

  13. Neratinib

    PUMA

    Advanced Breast Cancer

    phase 2 small molecule completed

    1 trial

  14. Neratinib

    PUMA

    Triple Negative Breast Cancer

    phase 2 small molecule active

    1 trial

  15. Neratinib

    PUMA

    Anatomic Stage I Breast Cancer

    phase 2 small molecule active

    1 trial

  16. Neratinib

    PUMA

    Solid Tumor, Adult

    phase 2 small molecule active

    1 trial

  17. Neratinib

    PUMA

    HER2-positive Breast Cancer

    phase 2 small molecule completed

    1 trial

  18. Neratinib

    PUMA

    Metastatic Breast Cancer

    phase 2 small molecule terminated

    1 trial

  19. Neratinib

    PUMA

    Early-stage Breast Cancer

    phase 2 small molecule active

    1 trial

  20. Neratinib

    PUMA

    Early Stage HER2+ Breast Cancer

    phase 2 small molecule completed

    1 trial

  21. Neratinib

    PUMA

    GastroEsophageal Cancer

    phase 2 small molecule active

    1 trial

  22. Neratinib

    PUMA

    Solid Tumors Harboring Somatic HER2 or EGFR Exon 18 Mutations

    phase 2 small molecule terminated

    1 trial

  23. Neratinib

    PUMA

    HER2 Amplified Breast Cancer

    phase 2 small molecule completed

    1 trial

  24. Paclitaxel

    PUMA

    Breast Cancer

    phase 2 small molecule completed

    1 trial

Drugs (1)

Search drugs →

  1. neratinib maleate

    NERATINIB MALEATE

    ORAL approved

Patents (1)

Search patents →

  1. US 10233206

    D-fagomine for the control of inflammatory processes related to an overactivation of the humoral immune response

    Expires Mon Mar 14 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

What is PUMA?

PUMA (PBYI) is a biotech company. headquartered in LOS ANGELES, CA, USA. listed on NYSE. NovaPharmaNews links 24 pipeline programs, 1 drug, and 1 patent to this profile..

What pipeline programs does PUMA sponsor?

We track 24 ClinicalTrials.gov-linked programs for PUMA, including Neratinib and 23 more. Open each program for phase, modality, NCT IDs, and indication details.

Where does PUMA company data come from?

Profiles combine SEC EDGAR (CIK/ticker), ClinicalTrials.gov sponsor links, FDA drug records, and USPTO patent metadata. See our data sources page. This profile is for professional reference, not investment advice.